CLOSE
CONTACT MITROPOLEOS 88, 54622 E-mail pathology@microdiagnostics.gr Τ. 2310 232 272 F. 2310 236 279
PredictArray Colon
Colorectal Cancer

I Choose PredictArray Colon

With PredictArray Colon we monitor the expression of MMR / MSI protein biomarkers (MLH1, PMS2, MSH2, MSH6), as well as the expression of protein biomarkers Amphiregulin and Epiregulin.

The Amphiregulin (AREG) and Epiregulin (EREG) biomarkers belong to the family of ligands of EGFR.

They do not occur in normal colon mucosa, whereas they are expressed in both adenomas and adenocarcinomas of the colon.

Studies have demonstrated that the overexpression of the above mentioned biomarkers is associated with response to EGFR- targeted therapies (targeted therapy).

In addition, high occurrence of EREG in metastatic adenocarcinoma of the large intestine is an independent prognostic biomarker favorable outcome.

What is the clinical utility of PredictArray Colon?

MSI / MMR analysis has significant clinical utility for patients with colorectal cancer. It is used

  1. for determining the prognosis of patients with stage II colon cancer,
  2. to identify patients with a higher risk of developing hereditary non- polyposis cancer large bowel (Lynch’s syndrome),
  3. as a response to the treatment with immune checkpoint inhibitors.

The Amphiregulin (AREG) and Epiregulin (EREG) biomarkers belong to the family of EGFR ligands. They are not occurred in normal colon mucosa, whereas they are expressed in both adenomas and adenocarcinomas of the colon.

  1. Studies have shown that overoccurence of these biomarkers is associated with responsiveness to EGFR- targeted therapies (targeted therapy).
  2. In addition, high expression of EREG in metastatic adenocarcinoma of the large intestine, is an independent prognostic biomarker favorable outcome.

How is PredictArray Colon conducted in microDiagnostics Ltd?

The tests are performed on the surgical specimen (paraffin blocks) that your histological examination was performed on. In our fully vertical Laboratory, the pathologist chooses the most appropriate & representative paraffin block, ensuring that the most appropriate specimen will be used for examinations. Qualitative and quantitative parameters are checked.

One touch approach – Strategic Sample Management, Time Saving

At our vertically integrated Laboratory, we handle your sample in such a way as to minimize its unnecessary waste:

  • The paraffin cube is inserted if it is possible once in the microtome to obtain tissue incisions by experienced web technologists.
  • Tissue sections are sequentially acquired in such way as to provide immunohistochemistry diagnosis and procedure, if required.
  • Ensure maintenance of tissue sections for further molecular testing.
  • Pathologists perform microdissection, in order to ensure the highest possible amount of cancer cells, removing all other necrotic cells or normal tissue that could affect the validity of the results.

Directly, the molecular biologist treats the tissue in a completely controlled environment with next generation sequencing (NGS), or polymerase chain reaction of real time (Real – time PCR) for the detection of mutations in genes of interest, or by immunohistochemistry method (IHC) on a certified platform.

The number and type of mutations examined are updated through a dynamic process according to current scientific research. It should therefore be recognized that there is a possibility that the list of genes in the order form may have changed (genes added or removed) when analyzing the sample in the laboratory.

In what types of cancers MSI occurs (microsatellite instability)?

MSI is more common in colorectal cancer and endometrial cancer. MSI has also been observed in cervical cancer, stomach cancer, glioblastoma, melanoma, ovarian cancer, prostate cancer.

Cancer Type:

Colorectal Cancer

Turn Around Time:

PredictArray Colon 4 days*

* If the sample needs to be enriched to ensure successful results, we will contact you

Frequently Asked Questions (FAQ)

MSI / MMR analysis has significant clinical utility for patients with colorectal cancer. It is used

  1. for determining the prognosis of patients with stage II colorectal cancer,
  2. to identify patients with a higher risk of developing hereditary non polyposis colorectal cancer (Lynch’s syndrome),
  3. for response to treatment with immune checkpoint inhibitors.

The biomarkers Amphiregulin (AREG) and Epiregulin (EREG) belong to the family of EGFR ligands. They are not expressed in normal colon mucosa, whereas they are expressed in both adenomas and adenocarcinomas of the colon.

  1. Studies have shown that overexpression of these biomarkers is associated with responsiveness to EGFR- targeted therapies (targeted therapy).
  2. In addition, high expression of EREG in metastatic adenocarcinoma of the large intestine is an independent prognostic biomarker favorable result.

The test is performed on the biopsy or ocectomy material (paraffin cube) that your histologic examination performed.

If your sample is not already in the Diagnostic File, Contact us immediately to arrange for it to be delivered safely and quickly to our laboratory. You will also need to complete, easily and quickly, the Consent Form.

Contact us at 2310 23 22 72 and we will immediately arrange for your quick sample transfer to our laboratory.

Via bank card, bank deposit, or online bank deposit

One of the primary concerns of microDiagnostics’ Ltd is the protection of your personal data as well as the strict adherence to the conditions protecting your genetic material and medical results.

In full compliance with the General Data Protection Regulation (GDPR) we ensure that you are aware and conscious for any examination will be conducted and we do not announce results via phone calls.

Book an appointment for PredictArray Colon

Fill in the fields below, press “Send” and we will contact you as soon as possible






Latest News / Blog

Start typing and press Enter to search

Shopping Cart